Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2017 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Fourth Quarter and Year End 2016 Financial Results

NEWARK, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases...
March 16, 2017 16:47 ET | Source: CymaBay Therapeutics, Inc.

CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23

NEWARK, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases...
March 09, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Two Investor Conferences in March

NEWARK, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases...
February 07, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference

NEWARK, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases...
February 02, 2017 09:15 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Pricing of Public Offering of Common Stock

NEWARK, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan...
February 01, 2017 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Proposed Public Offering of Common Stock

NEWARK, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan...
January 05, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate

NEWARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases...
January 03, 2017 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States

— Kowa to fully fund development through NDA approval— CymaBay to receive up to $205M in up-front and milestone payments— Conference call and webcast today at 4:30 pm ET NEWARK, Calif., Jan. 03,...
December 08, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors

NEWARK, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), today announced the appointment of Robert Booth, Ph.D. and Caroline Loewy to the company’s Board of...
December 07, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis

NEWARK, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat indications with high unmet...